Drew Boxler

New pleuromutilin antibiotic IV and oral tablets.

Humira successor indicated for adults with inadequate response or intolerance to methotrexate.

2019 cases greater than five-year trend.

Kinase inhibitor oral capsules.

Black box warns of increased risk of blood clots and death.

New program to fund community pharmacy reinvention efforts.

TNF blocker biosimilar to Humira (adalimumab, Abbvie).

CD20-directed antibody indicated for several cancers and other conditions.

Distributed by Invagen, a subsidiary of Cipla Ltd.

Fourth indication for the drug since 2014.

Combination drug indicated for infections caused by susceptible gram-negative bacteria.

Fourth approval for use in assessing myocardial perfusion and late gadolinium enhancement.

COMT inhibitor to be used as an adjunctive treatment to levodopa/carbidopa.

CBD market will grow by over 700% in 2019.

Nuclear export inhibitor indicated in combination with dexamethasone.

$359 million per year, and nearly 40 cumulative hours per week are spent mitigating shortages.

Unsupported claims of safety and effectiveness have concnerned the FDA. 

Bevacizumab-bvzr is an mAb endothelial growth factor biosimilar.

Complement inhibitor is the first treatment for the rare autoimmune disorder.

First treatment approved for the condition with nasal polyps.

New features to ease injection administration. 

Funds to help establish education and training for pharmacy technicians.

First non-insulin drug for pediatric use approved in nearly 20 years.

Indications include breast cancer, metastatic gastric cancer, and metastatic gastroesophageal junction adenocarcinoma.

DIR abuse might require Presidential and Congressional intervention.

Drug targets the CD79b protein on B-cells.

Pharmacists can earn up to 27 hours of CE. 

Results of a recent survey suggest employee-based drug abuse is a concern for many healthcare providers, though they don’t believe it can happen in their facilities.

Zerbaxa is a cephalosporin antibacterial and beta-lactamase inhibitor combination drug originally approved for abdominal and urinary tract infections.

Patients on Emgality experienced an average of 8.7 fewer weekly episodic cluster headaches.